Coeptis Therapeutics Holdings, Inc.

Finance Services · FORT LAUDERDALE · FL

Distress signal

Moderate confidence (50%)

Updated Sep 30, 2026, 12:04 AM

What is happening

Derived by rule set status-rules-2026.09.7

An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

Latest material event: Coeptis Therapeutics Holdings, Inc. was delisted from its exchange (Apr 24, 2026)

Every material event, newest first. History is never overwritten.

Coeptis Therapeutics Holdings, Inc. was delisted from its exchange
Apr 24, 2026
Delisting effective
- SEC EDGAR — “X0203 0001354457 Nasdaq Stock Market LLC 0001759186 Coeptis Therapeutics Holdings, Inc. 001-39669 801 S. Pointe Drive, Suite TH-1 Miami Beach FL FLORIDA 33139 (305) 671-3341 warrants 17 CFR 240.12d2-2(a)(3) Tara Petta AVP 2026-04-24”
Coeptis Therapeutics Holdings, Inc. received a delisting notice from its exchange
Jan 12, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 12, 2026, Coeptis Therapeutics Holdings, Inc. (the Company ) received a letter from the Listing Qualifications Department of The Nasdaq Capital Market LLC ( Nasdaq ) indicating that the Company is in violation of Nasdaq Listing Rules 5620(a) and 5810(c)(2)G) due to the Company s failure to hold an annual meeting of shareholders within twelve months of the end of the Company s fiscal year end of December 31, 2024 (the Annual Meeting Rule ). Under Nasdaq Listing Rules, the Co…”

Every material source used to build this profile.

SEC Company Submissions (TIER 1 · UNVERIFIED)
Z Squared Inc. — Finance Services (SIC 6199) — FORT LAUDERDALE, FL
View source record
SEC EDGAR (TIER 1 · UNVERIFIED)
X0203 0001354457 Nasdaq Stock Market LLC 0001759186 Coeptis Therapeutics Holdings, Inc. 001-39669 801 S. Pointe Drive, Suite TH-1 Miami Beach FL FLORIDA 33139 (305) 671-3341 warrants 17 CFR 240.12d2-2(a)(3) Tara Petta AVP 2026-04-24
View source record
SEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 12, 2026, Coeptis Therapeutics Holdings, Inc. (the Company ) received a letter from the Listing Qualifications Department of The Nasdaq Capital Market LLC ( Nasdaq ) indicating that the Company is in violation of Nasdaq Listing Rules 5620(a) and 5810(c)(2)G) due to the Company s failure to hold an annual meeting of shareholders within twelve months of the end of the Company s fiscal year end of December 31, 2024 (the Annual Meeting Rule ). Under Nasdaq Listing Rules, the Co…
View source record

Every derived status, with the rule that produced it.

DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:30 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:14 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:33 PM
The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.
DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 04:46 PM
The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.
DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 04:35 AM
The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.
UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:59 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.